3 edition of Current and future management of brain metastasis found in the catalog.
Includes bibliographical references and indexes.
|Statement||volume editors, Dong Gyu Kim, L. Dade Lunsford|
|Series||Progress in neurological surgery -- v. 26, Progress in neurological surgery -- v. 26.|
|The Physical Object|
|ISBN 10||9783805596176, 9783805596183|
|LC Control Number||2011044588|
Purpose of review The purpose of this review is to highlight the most recent advances in the management of brain metastases.. Recent findings Role of local therapies (surgery and stereotactic radiosurgery), new approaches to minimize cognitive sequelae following whole-brain radiotherapy and advances in targeted therapies have been reviewed.. Summary The implications for clinical trials and. In general, brain metastases occur in about 10% of metastatic cancer patients, but the incidence may be as high as 40–50% for some diagnoses such as lung cancer or HER2+ breast cancer. The brain is considered a “sanctuary site” for metastatic growth due to the presence of the blood–brain barrier, which excludes most systemic anticancer.
Barajas, RF & Cha, S , Imaging diagnosis of brain metastasis. in DG Kim & D Lunsford (eds), Current and Future Management of Brain Metastasis. . AbstractMany patients with lung cancer, breast cancer, and melanoma develop brain metastases that are resistant to conventional therapy. The median survival for untreated patients is 1 to 2 months, which may be extended to 6 months with surgery, radiotherapy, and chemotherapy. The outcome of metasta.
Brain metastasis, which commonly arises in patients with lung cancer, breast cancer and melanoma, is associated with poor survival outcomes and poses distinct clinical challenges. The brain. Brain Metastases From Small-Cell Lung Cancer—There have also been many studies evaluating the response of brain metastases from small-cell lung cancer to chemotherapy.[,] Kristensen et al reviewed 12 patient series with a total of patients published between and  Of the 12 studies, 11 used an epipodophyllotoxin and in.
Thomas Bewick, engraver.
Resilience in conflict
Drug development assay approaches, including molecular imprinting and biomarkers
Guide to periodicals and newspapers in the public libraries of Metropolitan Toronto 1988
soldiers heart and the effort syndrome.
The ferns and allied plants of Pennsylvania
role of denitrification in the nitrogen cycle of New England salt marshes
Words across the Channel; a modern Anglo-French vocabulary ....
1993/1994 Professional Relocation & Real Estate Referral Directory
The model theatre.
Current and Future Management of Brain Metastasis (Progress in Neurological Surgery, Vol. 25): Medicine & Health Science Books @ Brain metastases are a very common manifestation of cancer that have historically been approached as a single disease entity given the uniform association with Cited by: 8.
--Management of recurrent brain metastasis after radiosurgery --Future perspectives of brain metastasis treatment --Future perspectives of brain metastasis management.
Series Title: Progress in neurological surgery, v. Responsibility: volume editors, Dong Gyu Kim, L. Dade Lunsford. This book contains the most current information on the understanding of brain metastasis management. It is valuable reading for neurosurgeons, neuro-oncologists and radiation oncologists who are searching for the best all-round treatment for their patients.
Get this from a library. Current and future management of brain metastasis. [Dong Gyu Kim; L Dade Lunsford;] -- Recent strategies combining multiple modalities have opened up a whole new field of brain metastasis management focusing on disease control.
The management of brain metastasis in modern times is no. The future of brain metastasis management is predicated on personalized therapy targeted to specific tumor molecular pathways, such as those involved in blood–brain barrier transgression, cell–cell adhesion, and angiogenesis.
Brain metastases are often biologically distinct lesions compared to the primary tumor. Brain metastasis from lung cancer occupies a significant portion of all brain metastases.
About 15–20% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis during the course of the disease. The prognosis of brain metastasis is poor with median survival of less than 1 year. Whole-brain radiation therapy (WBRT) is widely usedCited by: Brain metastases are the most dreaded complication of systemic cancer, affecting approximatelypeople a year, a far greater incidence than primary brain tumors.
Advances in modern chemotherapy have led to an improved control of system cancers, often with agents that poorly penetrate the central nervous system, resulting in an increasing incidence of brain metastases.
Temozolomide. Temozolomide (TMZ) is an oral prodrug of the active metabolite of dacarbazine (5-(3-methyltriazenyl) imidazolecarboximide; or MTIC), is FDA approved for glioma, and has been used in advanced melanoma.  TMZ also has an advantage over dacarbazine in being able to cross the blood-brain barrier, which has made it a popular choice for patients with CNS disease.
The current treatment paradigm for brain metastasis depends on the patient’s overall health status, the primary tumor pathology, and the number and location of brain lesions.
What Causes Brain Metastases. Brain metastases are a common complication of primary cancers and a significant cause of morbidity and mortality – the rates of disease and death in certain populations – according to the American Association of Neurological Surgeons .These tumors do not start in the brain, but occur when cancer cells break away from a cancer in another area of the body and.
This book will bring current information on the presentation and management of patients with brain metastases, providing available data, giving guidelines that can be applied in day to day practice, updated information for neuro-surgeons, radiation oncologists, medical oncologists, and neuro-oncologists, as well as an overview for physicians in.
A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor.
The metastasis typically shares a cancer cell type with the original site of the cancer. Metastasis is the most common cause of brain cancer, with primary tumors that originate in the brain being less common.
Brain metastasis is always an indication of poor prognosis, with short overall survival, progression-free survival, and neurological deterioration .The incidence of brain metastases from unselected patients with different kinds of tumors ranges from 8% to 10% .The most common type of primary tumor is lung cancer, which accounts for approximately 20% of the brain metastases.
Original language: English: Title of host publication: Current and Future Management of Brain Metastasis: Publisher: S. Karger AG: Pages: Number of pages. The remarkable advances in the systemic therapy of metastatic melanoma have now extended the 1-year overall survival rate from 25% to nearing 85%.
Systemic treatment in the form of BRAF-targeted therapy and immunotherapy is slowly but surely proving its efficacy in the treatment of metatstatic brain metastases (MBM). Single-agent BRAF inhibitors provide an intracranial response.
TY - JOUR. T1 - Current and future management of brain metastasis. AU - Kim, Donggyu. AU - Lunsford, L. Dade. PY - /4/1. Y1 - /4/1. UR - Request PDF | Treatment of brain metastasis: current status and future directions | Purpose of review: The purpose of this review is to highlight the most recent advances in the management of.
Verma J, Jonasch E, Allen P, Tannir N, Mahajan A. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer. Nov 1. (21) Azim HA, Azim HA Jr. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.
Brain metastasis is a feared complication of cancer that is associated with a significant decrease in quality of life and a dismal prognosis. The risk of developing brain metastasis has been estimated at around 25% in all cancer patients; however, this incidence has been increasing in many common cancer types, particularly breast and NSCLC.
The incidence of brain metastases is increasing as cancer therapies improve and patients live longer, providing new challenges to the multidisciplinary teams that care for these patients.
Brain metastatic cancer cells possess unique characteristics that allow them to penetrate the blood–brain barrier, colonize the brain parenchyma, and persist in the intracranial environment. Methods. This is a review of current clinical practice based on an exhaustive literature search of PubMed, Embase, and Google Scholar.
A series of case studies is presented to provide outcomes of the effective management in BMs that have required treatment for the terminal stage of patients with cancer, and makes recommendations for future practice. Brain metastases (BMs) occur in 10% to 20% of adult patients with cancer, and with increased surveillance and improved systemic control, the incidence is likely to grow.
Despite multimodal treatment, prognosis remains poor. Current evidence supports use of whole-brain radiation therapy when patients present with multiple BMs. However, its associated cognitive impairment is a major .